Fig. 2 (abstract P192).From: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part twoObserved pembrolizumab serum concentrations from patients with melanoma treated with pembrolizumab plus ipilimumab in relation to the predicted concentration interval (gray) for pembrolizumab 2 mg/kg Q3W monotherapy (log scale)Back to article page